CA
ALNY icon

CoreCap Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

CoreCap Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.42K Buy
18
+16
+800% +$4.83K ﹤0.01% 2268
2026
Q1 		$662 Sell
2
-150
-99% -$51K ﹤0.01% 2607
2025
Q4 		$60.4K Sell
152
-228
-60% -$101K ﹤0.01% 1231
2025
Q3 		$173K Buy
380
+378
+18,900% +$154K 0.01% 847
2025
Q2 		$652 Hold
2
– – ﹤0.01% 2475
2025
Q1 		$540 Buy
+2
New +$514 ﹤0.01% 2667
2024
Q4 		– Sell
-2
Closed -$550 – 2854
2024
Q3 		$550 Hold
2
– – ﹤0.01% 2352
2024
Q2 		$486 Hold
2
– – ﹤0.01% 1450
2024
Q1 		$299 Buy
+2
New +$334 ﹤0.01% 2374
2022
Q4 		$475 Buy
+2
New +$427 ﹤0.01% 2176

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CoreCap Advisors's ALNY Position: Q2 2026 in Review

CoreCap Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 800% in Q2 2026, buying an estimated $4.83K and bringing the position to 18 shares worth $5.42K. The position accounts for ﹤0.01% of the portfolio, ranked #2268.

CoreCap Advisors first reported a position in ALNY in Q4 2022 and has held it in 10 quarters since. The position peaked at $173K in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • CoreCap Advisors held 18 shares of Alnylam Pharmaceuticals worth $5.42K as of Q2 2026.
  • CoreCap Advisors bought 16 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.83K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2268 holding.
  • CoreCap Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • CoreCap Advisors's Alnylam Pharmaceuticals position peaked at $173K in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.